Sterilization process for the excipient in SI-053 secured
Double Bond Pharmaceutical reports that transfer of the sterilization process for the excipient in SI-053 has been completed with satisfactory results. The process has been performed by a contract sterilization company in the EU. “This is an important step in the technology transfer process before manufacturing a GMP batch for our upcoming clinical trial” says Igor Lokot, CEO at Double Bond Pharmaceutical. This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted